NCT00707031 - GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin | Biotech Hunter

Enrollment

639

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Lixisenatide (AVE0010)

Self administered by subcutaneous injections once daily within the hour preceding breakfast.

DEVICE

Pen auto-injector

DRUG

Exenatide

Self administered by subcutaneous injections twice daily within the hour preceding breakfast and within the hour preceding dinner.

DEVICE

Prefilled pen injector

DRUG

Metformin

Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.

Trial Locations (18)

Sanofi-Aventis Administrative Office, Bridgewater

Sanofi-Aventis Administrative Office, Buenos Aires

Sanofi-Aventis Administrative Office, Vienna

Sanofi-Aventis Administrative Office, São Paulo

Sanofi-Aventis Administrative Office, Bogotá

Sanofi-Aventis Administrative Office, Hørsholm

Sanofi-Aventis Administrative Office, Helsinki

Sanofi-Aventis Administrative Office, Berlin

Sanofi-Aventis Administrative Office, Athens

Sanofi-Aventis Administrative Office, Budapest

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, Gouda

Sanofi-Aventis Administrative Office, Lysaker

Sanofi-Aventis Administrative Office, Warsaw

Sanofi-Aventis Administrative Office, San Juan

Sanofi-Aventis Administrative Office, Moscow

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Bromma